CAPR
CAPRICOR THERAPEUTICS, INC.
$25.80
+3.04%
$1.5B
No data for this timeframe.
Vol
Market Cap$1.5B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders50 funds
Inst. Value$586.4M
Inst. Activity11 buys / 5 sells
Insider Activity0B / 7S
Insider Net $-$6.8M
Reddit Sentiment82° Bullish
SEC Reports3
Press Releases1
Recent Activity
Aug 22, 2026
fda_pdufa
PDUFA: CAPR — Deramiocel in Duchenne muscular dystrophy cardiomyopathy — 2026-08-22
FDA target action date 2026-08-22 for CAPR (CAPRICOR THERAPEUTICS, INC.). Drug: Deramiocel. Indicati
May 26, 2026
Insider
Maurer Michael T was granted 80,000 shares
CHIEF COMMERCIAL OFFICER
May 18, 2026
Insider
Bergmann Anthony acquired via exercise 3,000 shares
CHIEF FINANCIAL OFFICER @ $1.39 ($4.2K)
May 13, 2026
Insider
Litvack Frank acquired via exercise 3,937 shares
Director @ $1.39 ($5.5K)
May 12, 2026
SEC
Capricor Therapeutics reported Q1 2026 EPS of -$0.59, missing consensus of -$0.54 by ~9.3%, with no revenue. The key cat
PRESS-RELEASE — Impact 5/10
May 4, 2026
SEC
Two insiders (CFO and EVP/General Counsel) exercised stock options and sold an aggregate of 50,000 shares at ~$31.70 eac
CLUSTER — Impact 2/10
Feb 28, 2026
SEC
Three major passive institutional investors — Morgan Stanley, Schwab, and UBS — significantly increased their positions
INST-CLUSTER — Impact 6/10
Inst.
STATE STREET CORP — DOUBLED
2,181,901 shares ($66.3M)
Price Targets
$54.11
+109.7% upside
Strong Buy
Current $25.80
Low $38.00
Median $54.00
High $63.00
9 analysts
$38.00
$63.00
Analyst Ratings
3Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 13, 2026 | B. Riley Securities | MAINTAIN | Buy → Buy |
| Mar 13, 2026 | Piper Sandler | REITERATE | Overweight → Overweight |
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.59 ▼ -12.3% | $-0.64 — $-0.47 | -3% YoY | 8 |
| Next Q | $0.47 ▲ +388.8% | $-0.66 — $2.56 | 188% YoY | 8 |
| Current FY | $-0.39 ▼ -122.7% | $-2.52 — $1.70 | 83% YoY | 8 |
| Next FY | $-0.76 ▼ -22.9% | $-2.57 — $0.62 | -98% YoY | 8 |
Latest Reports
NEUTRAL
PRESS-RELEASE
5/10
Capricor Therapeutics reported Q1 2026 EPS of -$0.59, missing consensus of -$0.54 by ~9.3%, with no revenue. The key cat
May 12, 2026
NEUTRAL
CLUSTER
2/10
Two insiders (CFO and EVP/General Counsel) exercised stock options and sold an aggregate of 50,000 shares at ~$31.70 eac
May 4, 2026
MIXED
Press
6/10
Capricor Therapeutics reported financial results for Q4 and full year 2025, highlighted by a strong cash position of $31
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $104.0M | — |
| STATE STREET CORP | $66.3M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $61.6M | — |
| RA CAPITAL MANAGEMENT, L.P. | $45.8M | NEW |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $32.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 26, 2026 | Maurer Michael | A | $0.00 |
| May 18, 2026 | Bergmann Anthony | M | $4.2K |
| May 13, 2026 | Litvack Frank | M | $5.5K |
| May 1, 2026 | Krasney Karen | M | $79.5K |
| May 1, 2026 | Krasney Karen | SELL | $792.5K |
Reddit Sentiment
82°▼
Bullish
Bearish
Neutral
Bullish
50 institutional holders with $586.4M total value (19,290,331 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 11 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3,421,815 | $104.0M | 17.7% | — |
| 2 | STATE STREET CORP | 2,181,901 | $66.3M | 11.3% | DOUBLED +163.0% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2,027,732 | $61.6M | 10.5% | — |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 1,507,844 | $45.8M | 7.8% | NEW |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,051,800 | $32.0M | 5.5% | — |
| 6 | GOLDMAN SACHS GROUP INC | 911,976 | $27.7M | 4.7% | — |
| 7 | Point72 Asset Management, L.P. | 821,179 | $25.0M | 4.3% | TRIM -55.4% |
| 8 | FMR LLC | 772,649 | $23.5M | 4.0% | DOUBLED +3794.6% |
| 9 | CITADEL ADVISORS LLC | 564,100 | $17.1M | 2.9% | — |
| 10 | CITADEL ADVISORS LLC | 539,232 | $16.4M | 2.8% | — |
| 11 | MORGAN STANLEY | 423,819 | $12.9M | 2.2% | TRIM -27.7% |
| 12 | BANK OF AMERICA CORP /DE/ | 415,483 | $12.6M | 2.2% | DOUBLED +672.0% |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 379,214 | $11.5M | 2.0% | — |
| 14 | CITADEL ADVISORS LLC | 336,500 | $10.2M | 1.7% | — |
| 15 | VANGUARD FIDUCIARY TRUST CO | 320,098 | $9.7M | 1.7% | — |
| 16 | D. E. Shaw & Co., Inc. | 315,000 | $9.6M | 1.6% | ADD +48.6% |
| 17 | BARCLAYS PLC | 314,792 | $9.6M | 1.6% | TRIM -57.9% |
| 18 | BALYASNY ASSET MANAGEMENT L.P. | 297,123 | $9.0M | 1.5% | NEW |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 259,900 | $7.9M | 1.3% | — |
| 20 | RTW INVESTMENTS, LP | 250,000 | $7.6M | 1.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | DOUBLED | 829,521 | 2,181,901 | +163.0% | $66.3M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 1,839,876 | 821,179 | -55.4% | $25.0M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 585,840 | 423,819 | -27.7% | $12.9M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 53,819 | 415,483 | +672.0% | $12.6M | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 13,621 | 185,372 | +1260.9% | $5.6M | 2026-Q1 |
| Nuveen, LLC | ADD | 90,951 | 162,906 | +79.1% | $5.0M | 2026-Q1 |
| Woodline Partners LP | TRIM | 219,086 | 137,655 | -37.2% | $4.2M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 12,755 | 59,575 | +367.1% | $1.8M | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 28,732 | 38,585 | +34.3% | $1.2M | 2026-Q1 |
| Legal & General Group Plc | DOUBLED | 3,969 | 37,138 | +835.7% | $1.1M | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 17,863 | 24,841 | +39.1% | $743.5K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 12,610 | 17,805 | +41.2% | $541.3K | 2026-Q1 |
| Mariner, LLC | TRIM | 21,450 | 15,417 | -28.1% | $468.7K | 2026-Q1 |
| Allworth Financial LP | TRIM | 3,329 | 2,067 | -37.9% | $62.8K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 93 | 270 | +190.3% | $8.2K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 23,152 | 30,995 | +33.9% | $943.00 | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 118,591 | 1,839,876 | +1451.4% | $53.1M | 2025-Q4 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 1,507,844 | — | $43.5M | 2025-Q4 |
| FMR LLC | DOUBLED | 23,690 | 922,634 | +3794.6% | $26.6M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 352,998 | — | $10.2M | 2025-Q4 |
| Woodline Partners LP | DOUBLED | 10,117 | 219,086 | +2065.5% | $6.3M | 2025-Q4 |
| NATIONAL BANK OF CANADA /FI/ | TRIM | 397,700 | 143,500 | -63.9% | $4.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 355,796 | 54,773 | -84.6% | $1.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 42,765 | 53,819 | +25.8% | $1.6M | 2025-Q4 |
| ALLIANCEBERNSTEIN L.P. | TRIM | 78,720 | 38,830 | -50.7% | $1.1M | 2025-Q4 |
5 unique insiders with 18 transactions. Net insider value: -$6.8M ($0.00 bought, $6.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 26, 2026 | Maurer Michael T | CHIEF COMMERCIAL OFFICER | AWARD | 80,000 | — | — |
| May 18, 2026 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | EXERCISE | 3,000 | $1.39 | $4.2K |
| May 13, 2026 | Litvack Frank | Director | EXERCISE | 3,937 | $1.39 | $5.5K |
| May 1, 2026 | Krasney Karen | EVP, GENERAL COUNSEL | EXERCISE | 25,000 | $3.18 | $79.5K |
| May 1, 2026 | Krasney Karen | EVP, GENERAL COUNSEL | SELL | 25,000 | $31.70 | $792.5K |
| May 1, 2026 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | EXERCISE | 25,000 | $3.18 | $79.5K |
| May 1, 2026 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | SELL | 25,000 | $31.70 | $792.5K |
| Apr 2, 2026 | Sabar Karimah Es | Director | SELL | 7,529 | $32.00 | $240.9K |
| Apr 2, 2026 | Sabar Karimah Es | Director | EXERCISE | 7,529 | $3.18 | $23.9K |
| Apr 1, 2026 | Sabar Karimah Es | Director | SELL | 53,735 | $31.03 | $1.7M |
| Apr 1, 2026 | Sabar Karimah Es | Director | EXERCISE | 53,735 | $4.86 | $261.2K |
| Mar 31, 2026 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | EXERCISE | 25,000 | $3.18 | $79.5K |
| Mar 31, 2026 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | SELL | 25,000 | $30.13 | $753.2K |
| Mar 31, 2026 | Krasney Karen | EVP, GENERAL COUNSEL | EXERCISE | 693 | $1.39 | $963.27 |
| Mar 31, 2026 | Krasney Karen | EVP, GENERAL COUNSEL | SELL | 25,000 | $30.12 | $752.9K |
| Mar 31, 2026 | Sabar Karimah Es | Director | EXERCISE | 61,265 | $4.86 | $297.7K |
| Mar 31, 2026 | Sabar Karimah Es | Director | SELL | 61,265 | $30.17 | $1.8M |
| Dec 30, 2025 | Krasney Karen | EVP, GENERAL COUNSEL | EXERCISE | 2,500 | $1.39 | $3.5K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
PRESS-RELEASE
5/10
Capricor Therapeutics reported Q1 2026 EPS of -$0.59, missing consensus of -$0.54 by ~9.3%, with no
May 12, 2026
NEUTRAL
CLUSTER
2/10
Two insiders (CFO and EVP/General Counsel) exercised stock options and sold an aggregate of 50,000 s
May 4, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Schwab, and UBS — significantly increa
Feb 28, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 15 analysts: 3 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$54.11 mean target
+109.7% upside
Strong Buy (3.00)
$38.00 Low
$63.00 High
| Metric | Value |
|---|---|
| Current Price | $25.80 |
| Target Low | $38.00 |
| Target Mean | $54.11 |
| Target Median | $54.00 |
| Target High | $63.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.59 | $-0.64 | $-0.47 | -3.1% | -12.3% | 1↑ 4↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$0.47 | $-0.66 | $2.56 | 187.5% | +388.8% | 0↑ 5↓ | $0.1B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-0.39 | $-2.52 | $1.70 | 83.0% | -122.7% | 2↑ 4↓ | $0.1B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-0.76 | $-2.57 | $0.62 | -98.4% | -22.9% | 1↑ 4↓ | $0.1B | 0.2% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.588 | |
| 7d ago | $-0.588 | |
| 30d ago | $-0.523 | -0.064 |
| 60d ago | $-0.519 | -0.069 |
| 90d ago | $-0.508 | -0.080 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 13, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 15, 2025 | B. Riley Securities | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
82°
Bullish
Bearish
Neutral
Bullish
7 mentions
7 bullish
0 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 19, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Apr 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
CAPR: My Current Favorite Biotech
▲ 1
💬 0
⚡ 0.5
CAPR: My Current Favorite Biotech
▲ 1
💬 0
⚡ 0.5
CAPR: My Current Favorite Biotech
▲ 1
💬 0
⚡ 0.5
Aug 22, 2026
fda_pdufa
PDUFA: CAPR — Deramiocel in Duchenne muscular dystrophy cardiomyopathy — 2026-08-22
FDA target action date 2026-08-22 for CAPR (CAPRICOR THERAPEUTICS, INC.). Drug: Deramiocel. Indication: Duchenne muscular dystrophy cardiomyopathy. PD
Jun 8, 2026
other
Capricor Therapeutics to Present at Upcoming Investor Conferences
<p align="justify">SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=45EzjD_MRxDC7t6_7E1adJDGYCNn-3Ty
May 14, 2026
short_interest
FTD: CAPR — 38,274 shares ($1.2M) failed to deliver
Settlement: 20260514, Price: $30.33, FTD Value: $1,160,850.42, CAPRICOR THERAPEUTICS INC COM
May 12, 2026
earnings
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="justify">SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=K5eyJeCiIsu7AF5u4GEhaiwxUG4lAkL1M
May 12, 2026
earnings_calendar
CAPR Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
earnings_calendar
CAPR Q1 2026 Earnings Scheduled — 2026-05-07
May 4, 2026
earnings
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
<p align="center">– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET –</p>
Apr 14, 2026
short_interest
FTD: CAPR — 45,351 shares ($1.6M) failed to deliver
Settlement: 20260414, Price: $34.54, FTD Value: $1,566,423.54, CAPRICOR THERAPEUTICS INC COM
Mar 18, 2026
short_interest
FTD: CAPR — 35,233 shares ($1.1M) failed to deliver
Settlement: 20260318, Price: $31.19, FTD Value: $1,098,917.27, CAPRICOR THERAPEUTICS INC COM
Mar 12, 2026
earnings
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
<p align="justify">SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=E8X3RyCnUdAW7HTL09B4e4_ntOFXs-H
Mar 12, 2026
other
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
<p align="justify">SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dz7hwIR-mhOUux56K5VsnKmUsiEhhZR
Mar 12, 2026
earnings_calendar
CAPR Q4 2025 Earnings After Market Close — 2026-03-12
Mar 10, 2026
other
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
<p align="justify">SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=BuHJTBj3kfGP7RkovcduMOZe4lk4eua
Mar 10, 2026
other
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
<p align="justify">SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=BuHJTBj3kfGP7RkovcduMOZe4lk4eua
Mar 9, 2026
earnings
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
<p align="center">– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET –</p>